Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2024 Nov 15;6(4):104-113.
doi: 10.46989/001c.124593. eCollection 2024.

Nurses' reported training needs for advanced cell therapies: a survey on behalf of the Nurses Group of the EBMT

Michelle Kenyon  1 , Sarah Jayne Liptrott  2   3 , Annika Kisch  4   5 , Jarl Mooyaart  6 , Brian Piepenbroek  7 , Daphna Hutt  8 , Isabel Salcedo  9 , Annalisa Ruggeri  10 , Cristian Chabannon  11 , Rose Ellard  12 , John Murray  13
Affiliations

Nurses' reported training needs for advanced cell therapies: a survey on behalf of the Nurses Group of the EBMT

Michelle Kenyon et al. Clin Hematol Int. .

Abstract

Background: Advanced Therapy Medicinal Products (ATMPs) for human use have advanced globally with the rapid adoption of Chimeric Antigen Receptor T-cell (CAR-T) therapies in haemato-oncology. CAR-T cell therapy and ATMPs have unique, significant acute and chronic toxicities, and appropriate patient care is crucial. Significant challenges, including the need for nurse education and training, accompany optimal patient success and benefits.

Objectives: This study aimed to describe nurses' training needs in relation to ATMP management and patient care.

Methods: A cross-sectional online survey was performed by the European Society for Blood and Marrow Transplantation, based on a previously tested questionnaire developed in the UK.

Findings: 109 complete responses from 86 different centers from 24 countries were returned (1207 distributed). Over 1/3 reported experience delivering licensed ATMPs (CAR-T). High-priority training areas included a general introduction to ATMPs, toxicity management, product-specific information, and regulatory frameworks for ATMPs. A clear need for ATMP-specific training exists and is regarded as important. Training prior to implementation is key and should be supported by ongoing competency maintenance. Counseling, patient support, and long-term follow-up are identified for future training and opportunities for nurse experience sharing in this rapidly evolving field.

Keywords: ATMP; CAR-T; cellular therapy; education; gene therapy; nursing care.

PubMed Disclaimer

Conflict of interest statement

Michelle Kenyon: Mallinkrodt, Jazz, Sanofi Sarah Jayne Liptrott: No competing interests were disclosed. Annika Kisch: No competing interests were disclosed. Jarl Mooyaart: No competing interests were disclosed. Brian Piepenbroek: No competing interests were disclosed. Daphna Hutt: No competing interests were disclosed. Isabel Salcedo: No competing interests were disclosed. Annalisa Ruggeri: No competing interests were disclosed. Christian Chabannon: Bellicum Pharmaceuticals, BMS, Jazz, Janssen Pharmaceuticals, Kite / Pharma, Novartis, Sanofi SA Rose Ellard: Kite Gilead, Novartis, Janssen, BMS Celgene. John Murray: Therakos, Jazz Pharmaceuticals, Janssen and Gilead/Kite

Similar articles

See all similar articles

References

    1. Hematopoietic cell transplantation and cellular therapy survey of the EBMT: monitoring of activities and trends over 30 years. Passweg J. R., Baldomero H., Chabannon C., Basak G. W., de la Cámara R., Corbacioglu S., Dolstra H., Duarte R., Glass B., Greco R., Lankester A. C., Mohty M., Peffault de Latour R., Snowden J. A., Yakoub-Agha I., Kröger N., European Society for Blood and Marrow Transplantation (EBMT) 2021Bone marrow transplantation. 56(7):1651–1664. doi: 10.1038/s41409-021-01227-8. https://doi-org.eoc.swissconsortium.ch/10.1038/s41409-021-01227-8 - DOI - DOI - PMC - PubMed
    1. Management of adults and children receiving CAR T-cell therapy: 2021 best practice recommendations of the European Society for Blood and Marrow Transplantation (EBMT) and the Joint Accreditation Committee of ISCT and EBMT (JACIE) and the European Haematology Association (EHA) Hayden P. J., Roddie C., Bader P., Basak G. W., Bonig H., Bonini C., Chabannon C., Ciceri F., Corbacioglu S., Ellard R., Sanchez-Guijo F., Jäger U., Hildebrandt M., Hudecek M., Kersten M. J., Köhl U., Kuball J., Mielke S., Mohty M., Murray J., Yakoub-Agha I. 2022Annals of oncology: official journal of the European Society for Medical Oncology. 33(3):259–275. doi: 10.1016/j.annonc.2021.12.003. https://doi-org.eoc.swissconsortium.ch/10.1016/j.annonc.2021.12.003 - DOI - DOI - PubMed
    1. The expanding role of the clinical haematologist in the new world of advanced therapy medicinal products. Lowdell M. W., Thomas A. 2017British journal of haematology. 176(1):9–15. doi: 10.1111/bjh.14384. https://doi-org.eoc.swissconsortium.ch/10.1111/bjh.14384 - DOI - DOI - PubMed
    1. Calmels B. In: The EBMT/EHA CAR-T Cell Handbook. Kröger N., Gribben J. G., Chabannon C., Yakoub-Agha I., Hermann E., editors. Springer Open; Educational Needs for Cell Processing Facility Personnel; pp. 219–220. - DOI - PubMed
    1. Delivery of adoptive cell therapy in the context of the health-care system in the UK: challenges for clinical sites. Pillai M., Davies M. M., Thistlethwaite F. C. 2020Therapeutic advances in vaccines and immunotherapy. 8:2515135520944355. doi: 10.1177/2515135520944355. https://doi-org.eoc.swissconsortium.ch/10.1177/2515135520944355 - DOI - DOI - PMC - PubMed

LinkOut - more resources